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OBJECTIVES: 1) To evaluate the relationship between asthma education and five 
measures of HRQoL–general health (GH), physical distress (PD), mental distress 
(MD), activity limitation (AL) and unhealthy days (UD), and 2) To find factors 
associated with receiving asthma education. METHODS: Data of adult US 
asthmatic individuals were obtained from the 2009 BRFSS ACBS. Asthma 
education comprises of five components: receiving asthma management plan, 
monitor peak flow, recognize early signs or symptoms of an asthma episodes, 
respond to early signs or symptoms of an episode, and change environment to 
improve asthma. Those who received all five components were labeled as 
“asthma education” group and those who received none of the five components 
were labeled as “no asthma education” group. Group comparisons for HRQoL 
measures were done by Chi-square test using SAS 9.2® RESULTS: From a total of 
1472 individuals identified in this study, 54.55% did not receive all five 
components of asthma education. Individuals in the asthma education group 
reported significantly better GH (57.70% vs. 49.81%, p=0.002), fewer PD (64.28% vs. 
59.15%, p=0.046) and fewer UD (52.32% vs. 44.46%, p=0.002). No significant 
differences were found for MD and AL due to high proportion of study 
individuals (>70%) reporting better HRQoL for these measures. Proportion of 
asthma education for all five components was significantly lower in; elderly, 
males, less than high school education, retired, and those with low income. 
CONCLUSIONS: Asthma education showed a positive impact on HRQoL 
measures – GH, PD and UD. Factors associated with non-receipt of all five 
asthma education components were age, gender, education, employment and 
income level. Interventions to encourage asthma education and overcome the 
inequality for the receipt of asthma education should be designed.  
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OBJECTIVES: To study the health-related quality of life (HRQOL) of 300 patients 
with type 2 diabetes mellitus at a clinical setting of a tertiary care hospital. 
METHODS: The socio-demographic and clinical parameters of this group of 
patients were collected and their HRQOL was assessed using a generic 
questionnaire, the WHOQOL-BREF. RESULTS: The results revealed that in our 
study the patients were predominantly male (58%). The mean age of the study 
participants was found to be 56.97±11.57 years with 67.6% of the patients above 
the age of 50 years. Seventy-six percent of patients reported suffering from at 
least one other chronic non-diabetic medical condition like hypertension 
(63.33%) and/or hyperlipidemia (40.63%). Diabetic complications were also 
prevalent (62.4%). The highest mean domain score in our study population was 
in the social relationship domain (13.10±2.33), and the lowest was in the 
environment domain. The respondents with a lower family income, less 
education, increased age, female gender, single marital status and a rural 
background reported significantly lower HRQOL scores. CONCLUSIONS: Diabetes 
mellitus is a chronic disease of life long duration affecting about 9% of India’s 
population. The number of people with diabetes is steadily increasing in India 
due to population growth, aging, urbanization and the increasing prevalence of 
obesity as well as physical inactivity. By identifying specific subsets of patients 
most likely to benefit from specialized care from health care providers, this 
study contributes by providing important data that may have direct implications 
for health care providers in their practice.  
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OBJECTIVES: To identify the socio-economic factors that influence the non 
renewal decision of National Health Insurance Policy Holders. METHODS: An 
analytical cross sectional survey was conducted. Four hundred and fifty-four 
(454) subjects from the non renewal list at the Bekwai Mutual Health Insurance 
Scheme were randomly selected and interviewed using validated structured and 
pre-tested questionnaires. A hand delivered questionnaire was used to collect 
data with the help of three trained research assistants after consenting process 
had been completed. The data was entered analyzed using SPSS version 16 and 
analysis was done for the various study variables. All statistical tests were run at 
95% confidence interval and at 5% significance level. RESULTS: Two hundred two 
(44.5%) of the respondents reside in the urban setting while 252 (55.5%) of 
respondents was from the rural area. Eighty-seven out of the 454 respondents 
representing 19.2% were traders while 84 (18.5%), 80 (17.6%), 54 (11.9%) and 16 
(3.5%) respectively. Most respondents were married suggesting that decoupling 
the exemption of children under 18 years old from parents has served as a 
disincentive to the registration of parents. Urban respondents who had no 
formal education and primary school level were 3.15 times and 2.32 times more 
likely not to renew their health insurance, as compared with rural respondents. 
Artisans, clericals and students were 0.80 times, 0.95 times, and 0.79 times less 
likely not to renew their health insurance respectively. Respondents who fall 
within income brackets 1-100, 101-200 and 201-300 were 0.54 times, 0.72 times 
and 0.78 times less likely not to renew health insurance. CONCLUSIONS: Socio-
economic factors, such as education, income, marital status and employment 
had influence on the retention decisions. Implementing pro-poor social 
interventions and conducting further studies to access the influence of beliefs, 
knowledge and status of health insurance on health care utilization could be 
helpful.  
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OBJECTIVES: The Secretary of the Department of Health and Human Services is 
empowered by law to base Medicare reimbursement on the United States 
Preventive Services Task Force (USPSTF) recommendations (Grade A, benefits 
certainty high; B, benefits certainty moderate; and D, recommends against 
service). The purpose of this study was to evaluate the congruence between the 
USPSTF recommendations and their respective Medicare coverage policies. 
METHODS: The USPSTF website and Medicare preventive services guide were 
reviewed through December 2012 to study alignment between the USPSTF 
recommendations and Medicare coverage policies. Two reviewers independently 
extracted the data. We excluded USPSTF recommendations that were: I or C 
grade, inactive, for injury/violence, only valid for people <65 years, for preventive 
medication, or update-in-progress. Included USPSTF recommendations were 
categorized by therapeutic area (e.g., cancer), sub-therapeutic area (e.g., breast 
cancer), and recommendation class (i.e., screening and counselling). More than 
one recommendation for same sub-therapeutic area was treated separately. 
RESULTS: A total of 128 USPSTF recommendations were found, of which 37 
(28.90%) were included in the analysis. The largest percentage of recom-
mendations were for cancer (29.72%, n=11), followed by infectious diseases 
(27.02%, n=10). The vast majority were for screening (91.89%, n=34). Most of the 
Grade A and B USPSTF recommendations (94.11%, n=16) were covered by 
Medicare. However among USPSTF grade D recommendations, 35% (n=7) were 
also covered by Medicare (e.g., prostate-specific antigen based prostate cancer 
screening). As per the health care reform’s objective of investment in prevention 
and illness, all of the included USPSTF recommendations were covered by 
Medicare without out-of-pocket payment, except one (i.e., tobacco cessation 
counselling). CONCLUSIONS: Medicare coverage policies for preventive services 
should be re-examined, especially those for which the USPSTF has issued grade 
D recommendations. Continuing such grade D recommendations without any 
established benefits will likely lead to unnecessary health care services and 
costs.  
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OBJECTIVES: To explore the perceptions and knowledge of prescribers towards 
adherence to standard treatment guidelines for malaria in two cities of Pakistan; 
Islamabad (national capital) and Rawalpindi (twin city). METHODS: A descriptive, 
cross sectional study design was used to evaluate the knowledge and 
perceptions of prescribers regarding adherence to standard treatment regimen 
for malaria. A questionnaire was developed through focused group discussions 
and distributed randomly to a sample of 360 prescribers in the two cities. 
Kruskal-Wallis test (p≤0.05) was used to compare the knowledge of prescribers 
(regarding standard malaria regimen) having different designations, level of 
experiences and their work affiliation with different levels of health care 
facilities. While Mann Whitney test (p≤0.05) was used to compare the knowledge 
among different genders of prescribers practicing in public and private health 
care facilities in the two cities. RESULTS: A significant difference (p≤0.05) among 
the knowledge of prescribers (regarding standard treatment regimen for malaria) 
having different designations, level of experience, working in different sectors 
and levels of health care facilities in the two cities was observed. However, no 
significant difference (p≤0.05) in the knowledge of different genders of 
prescribers was observed. CONCLUSIONS: The results of the present study 
showed that the overall knowledge of prescribers regarding standard treatment 
regimen for malaria in the two cities of Pakistan was inadequate. Most of the 
prescribers were unaware of correct standard treatment regimen for the 
treatment of Plasmodium falciparum and Plasmodium vivax.  
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OBJECTIVES: To determine the clinical and economic effects and components of 
integrated care programs to improve management of chronic diseases in Europe 
on the basis of systematic reviews and meta-analyses. METHODS: A systematic 
literature review was performed. Medline, Scopus, EMBASE, WHOLIS and The 
Cochrane Library of Systematic Reviews for English and German language 
articles were searched for English- and German language articles from 2002 to 
2012. Articles were included if an explicit research question was defined, 
focussed on care that involves more than one provider, reported clinical 
outcomes of care, and employed acceptable experimental or quasi-experimental 
study designs as defined by the Cochrane Effective Practice and Organization of 
Care Group. More than 50% of included primary studies had to be RCT’s and 
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conducted in Europe. RESULTS: The search identified 25.135 articles, 889 titles 
were included for further screening and 409 abstracts for the article review step. 
A total of 308 abstracts did not meet the inclusion/exclusion criteria, leaving a 
pool of 101 articles for full text evaluation. Overall, 10 systematic reviews were 
identified, with 238 primary studies, 129 conducted in Europe. The sample sizes 
from the included primary studies from Europe revealed 20 to 15.343 patients 
with a mean of 514. Chronic conditions investigated were: heart failure, chronic 
obstructive pulmonary disease, diabetes, and cancer. Of the outcomes more 
frequently studied, integrated care appeared to improve quality of life and 
reduce hospitalization. But often results remained inconclusive. CONCLUSIONS: 
Providing a conclusion across the different chronic conditions is not possible. 
Therefore, only disease specific conclusions can be drawn. Our review suggests 
that integrated care might be advantageous for specified groups of patients, e.g. 
heart failure. Furthermore, it remains unclear which specific component is 
associated with the highest benefit for patients across chronic conditions.  
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OBJECTIVES: For SCD patients, inadequate care during pediatric to adult 
transition may result in increased emergency department (ED) utilization. 
Emergency department reliance (EDR: total ED visits/total ambulatory 
[outpatient+ED] visits) identifies the proportion of ED visits in relation to all 
ambulatory visits. This study aimed at investigating age-related patterns of EDR 
and associated health care costs in SCD patients. METHODS: State Medicaid data 
from Florida, New Jersey, Missouri, Iowa, and Kansas were analyzed. Patients 
with ≥2 SCD diagnoses (ICD-9 282.6x) and ≥1 blood transfusion were included. 
Quarterly rates of EDR and SCD complication-related ED visits as well as health 
care costs were evaluated. Based on published thresholds, high EDR was defined 
as >0.33. Regression analyses were used to assess risk factors for high EDR and 
calculate adjusted costs difference between patients with high versus low EDR. 
RESULTS: A total of 3208 patients were identified; mean (SD) observation period 
was 6.5 (3.2) years. Mean ED visits/quarter increased from 0.76 to 2.23 between 
age 15 and 23, reaching a peak of 2.9 at age 36. The most common SCD 
complication-related ED visits were pain, infection, and pneumonia. EDR rose 
from 0.15 to 0.29 between age 15 and 23, and remained high thereafter. Patients 
were more likely to have high EDR during the post-transition period (≥18 years 
old, odds ratio [OR]: 2.38, p<0.001) and when experiencing an SCD complication 
(OR: 4.18, p<0.001). Patients with high EDR incurred higher inpatient and ED 
costs, resulting in higher total costs (high vs. low EDR, adjusted costs difference, 
OP: -$285; IP: $3,485; ED: $120; Rx: -$91; total: $3,086, p<0.001 for all). 
CONCLUSIONS: Compared to children, SCD patients transitioning to adulthood 
relied more on ED for their care and those with high EDR incurred higher health 
care costs, highlighting the need to improve access to care for transitioning and 
adult SCD patients.  
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OBJECTIVES: Pharmacists are qualified to provide many services that are core to 
integrated care models. Expanding services to diverse patient populations will 
increase pharmacists’ value. This study describes the experience, preliminary 
outcomes and revenue model justification associated with the implementation 
of pharmacist-led care for patients with respiratory disorders. METHODS: 
Medical and billing record review was performed on patients with respiratory 
symptoms referred to the pharmacist from May 2011 to September 2012 within a 
community-based, medical home, primary care practice. Patients referred were 
those with respiratory symptoms in which the physician sought objective lung 
function data and additional support to assist in properly diagnosing and 
treating the patient. Pharmacist interventions included collection of a detailed 
pulmonary and medication history, spirometry, and on applicable patients, dis-
ease state education, medication care plans and device education, and smoking 
cessation. Outcomes described included quality and results of spirometry 
testing, pharmacist recommendations, recommendations for specialist care and 
payment for services. RESULTS: Thirty-four patients (76.5% female; mean 
age=49.6±17.6) were seen by the pharmacist and assessed by spirometry. 
Spirometry met American Thoracic Society quality measures in 82.5% of tests 
with the following results: 64.7% normal, obstruction (8.8% mild, 14.7% moderate, 
2.9% severe), and 8.8% probable restriction. Pharmacist recommendations that 
were implemented included the use of short-acting-beta-agonists (23.5%), 
corticosteroids (20.6%), anti-cholinergics (14.7%), and long-acting-beta-agonists 
(11.8%). Smoking cessation was recommended for 11.8% of patients and 44.1% 
received specialist referrals. The mean overall payment for the services provided 
at these visits was $144.43±36.34. CONCLUSIONS: Pharmacist involvement in the 
care of patients with respiratory disorders provided valuable, quality lung 
function data and care plan recommendations to physicians and education to 
patients. These preliminary results support the pharmacist expanding their role 
in the medical home by providing physician/patient care services, including 
spirometry, to patients with respiratory disorders from both a clinical and 
economic perspective.  
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OBJECTIVES: To review the literature published within the last decade related to 
drug-related problems and medication errors in Sub-Saharan Africa. This article 
provides a discussion on pharmaceutical care, with a focus on economic 
outcomes. METHODS: A search using Medline, Embase was conducted over the 
timeframe January 2002–December 2012 using key words such as: Sub-Saharan 
Africa, medication errors, economics, and pharmaceutical care. The abstract 
and/or full text of each article was reviewed. RESULTS: Twenty studies were 
identified for review. The most common problems in the pharmacy system were 
improper labeling, counterfeit drugs, lack of patient education, and inadequate 
drug distribution. The lack of electronic medical records and payment systems 
prevent the assessment of clinical cost outcomes. In a study conducted by the 
University of Benin, of 1500 pharmacists, 93% reported that they would be willing 
to participate in “any training program to enable them to practice pharma-
ceutical care.” There is a lack of pharmacists able to provide pharmaceutical care 
as defined as the direct, responsible provision of medication-related care 
designed to achieve definite outcomes. The shortage of pharmacists is due to 
few training institutions, migration, inadequate pay and poor working 
conditions. Specifically, 25% of the world’s global burden of disease is in Sub 
Saharan Africa, while this area comprises 3% of the world’s health workers. 
These factors contribute to an increase in medication errors. CONCLUSIONS: 
Sub-Saharan Africa lacks the necessary governmental regulation to ensure a 
decrease in medication errors. The government may consider streamlining their 
drug distribution system through the enforcement of regulations and the use of 
information technology in the health care delivery system. Additional studies are 
needed to examine economic outcomes. Several studies provide information on 
cost effectiveness and quality of life, but these studies are specific to the 
HIV/AIDS population.  
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OBJECTIVES: Health care fraud is a long-standing problem, accounting for $75 
billion in 2009. Congress amended the False Claims Act (FCA) in 1986 to allow qui 
tam relators (“whistleblowers”) to receive up to 30% of anti-fraud recoveries. 
Most studies investigate health care fraud involving the pharmaceutical 
industry, so it has not been possible to contextualize fraud involving health care 
sectors other than the pharmaceutical industry. Herein, we review all recently 
concluded major federal health care fraud investigations. METHODS: All cases 
involved health care corporations and federal FCA. Data were collected from 
Lexis/Nexis News (search terms: “Health care fraud”, “False Claims Act” and “Qui 
tam”), the Taxpayers against Fraud and the DOJ websites (2006-2011). Only cases 
with recoveries over $5 million (“major cases”) were included. Data were 
abstracted on allegations, financial settlements, occupations of and payments to 
qui tam relators. Cases are reported separately as qui tam- versus non-qui tam-
initiated to document whether the Congressional intent to encourage 
whistleblowing achieved its intended goal. RESULTS: Between 2006 and 2011, 123 
major qui tam health care FCA cases concluded, totaling $15.7 billion in 
recoveries (mean recovery: $128 million). Billing fraud, kickbacks, off-label 
marketing, and marketing unsafe pharmaceuticals were the most commonly 
implicated activities. Pharmaceutical manufacturers accounted for 31% of, and 
$11.3 billion (70%) in recoveries among qui tam relator cases. Also, 52 non-qui 
tam cases closed in this 5-year period, totaling $3.7 billion in recoveries (mean 
recovery: $71 million). Implicated activities included fraudulent billing, 
inappropriate financial relationships, off-label marketing, or marketing unsafe 
pharmaceuticals. CONCLUSIONS: In conclusion, federal investigations of fraud 
and abuse involving health care are increasing in both depth and breadth,  
and qui tam relators have an important role in detecting important fraud and 
abuse.  
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OBJECTIVES: The Patient Protection and Affordable Care Act will expand the 
eligibility of the Medicaid program to millions of Americans in 2014. Utilizing 
more generic drugs and setting appropriate pharmacy reimbursement rates 
could result in substantial savings to the Medicaid program. This study assessed 
2011 state-level, fee-for-service Medicaid generic and brand drug utilization and 
expenditures, and pharmacy reimbursement rates. METHODS: Medicaid fee-for-
service outpatient pharmacy utilization and expenditures, and reimbursement 
rates (ingredient cost and dispensing fees) for the year 2011 were extracted from 
state-level data provided from the Centers for Medicare and Medicaid Services. 
Descriptive analyses were performed for all variables in the data set. Linear 
regression analysis was performed to assess the relationship between ingredient 
cost, dispensing fees and drug utilization. The significance level for variables was 
0.05. RESULTS: Fee-for-service Medicaid expenditures (n=46 states) reached $27.8 
billion with drug utilization accounting for 173.4 million claims in 2011. Generic 
expenditures represented 17.3% of total expenditures (range=10.3%-29.2%) and 
